Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar desktop iconMarkt Monitor

Franse aandelen« Terug naar discussie overzicht

Biophytis ontploft, Integragen en Theradiag next!

395 Posts
Pagina: «« 1 ... 7 8 9 10 11 ... 20 »» | Laatste | Omlaag ↓
  1. i know it 21 april 2020 10:23
    About BIOPHYTIS 
    Biophytis SA is a clinical-stage biotechnology company specialized in the development of drug candidates to slow down degenerative processes and improve functional abilities in patients with age-related diseases, especially neuro muscular diseases.Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in the United States and Europe. A pediatric formulation of BIO101 is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company plans to start the clinical development in H2 2020.Sarconeos (BIO101) will also be developed as a treatment for Covid-19 (Coronavirus) for which the company has filed a clinical trial application with the French Regulatory Authority (ANSM).The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). For more information www.biophytis.com.

    5 Posts

    Aanta

  2. i know it 21 april 2020 10:37
    Correction - Biophytis launches a Public Offering of
    Share Subscription Warrants (BSA) with an Irreducible Priority
    Subscription Period for Existing Shareholders
    Paris (France), Cambridge (Etats-Unis), April 21 , 2020, 8:00 a.m. CEST – BIOPHYTIS (Euronext Growth
    Paris: ALBPS), today issued a correction of the press release issued on April 7, 2020, in order to
    consolidate important information relating to the offer to the public of Share Subscription Warrants
    (BSA) with an irreducible priority period for shareholders. This information was included until today in
    the Synthetic Information Document (DIS) posted on the Biophytis website on April 7, 2020. However,
    under this transaction, the Company was not subject to the publication of a DIS.

    Below is the corrected press release:
    Paris, (France), Cambridge (Massachusetts, United States), Biophytis SA (Euronext Growth Paris: ALBPS
    a clinical-stage biotechnology company specialized in the development of drug candidates for treatment
    of aged related diseases, especially neuromuscular diseases, announced on April 7, 2020 the launch of
    a public offering of 7,445,123 Share Subscription Warrants (BSA), which could be increased to 7,475,708
    BSA, by way of a public offering with an irreducible priority subscription period for existing shareholders,
    as well as an extension clause.
    Offering price
    The subscription price will be €0.06 per BSA for a total amount of €446,707.38 and €448,542.48 if the
    extension clause is exercised.
    BSA Offering
    The proposed issuance of the 7,445,123 BSA, to be subscribed in cash, will be carried out with
    shareholders’ preferential subscription rights removed. The Offer will include (i) a priority period for
    shareholders on an irreducible basis only, with 3 BSA for every 16 shares held as of April 8, 2020
    (operation settled at this date) (rounded to the higher unit if the number of shares is not a multiple of
    16) and (ii) an extension clause to increase the issue to 7,475,708 BSA.
    Shareholders registered as of April 8, 2020 (operation settled at this date) will benefit from a non-
    negotiable and non-transferable subscription priority period, from April 9, 2020 to April 21, 2020
    included at 12:00 p.m. (Paris time). As a result, all shares purchased on 7
    th and 8th April 2020 will not
    benefit from the priority period.
    As part of the priority period, the Company's shareholders will be able to subscribe on an irreducible
    basis to the extent of their shares in the Company's capital pursuant to the terms set out above. There
    are no plans to allow subscriptions on a reducible basis during the priority period.
    Unsubscribed BSAs will then be offered first to the Company's employees and executive officers within
    the limits of their requests. The Priority Period relates to the initial issuance amount, excluding the
  3. forum rang 4 RW1963 21 april 2020 12:21
    quote:

    i know it schreef op 21 april 2020 10:39:

    Waarom denken mensen dat het naar 0,30 cent gaat ??? Lees dan eens goed ! Voor bestaande aandeelhouders die er al langer inzitten hebben een voordeel. Maar op zeker boven de 2 euro eind van de week
    JAMMER!
    Je bent al weer flink gezakt t.o.v. een eerdere voorspelling.

    i know it 17 april 2020 17:19

    Oh ja tot ver over de 3 euro...
395 Posts
Pagina: «« 1 ... 7 8 9 10 11 ... 20 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.